Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved to change the dosage and administration of agents used in Takeda Pharmaceutical's central precocious puberty (CPP) treatment Leuplin for injection 1.88 and Leuplin for injection 3.75.
Subscribe to our email newsletter
According to the latest move, the maximum allowable dosage of the drug for CPP changes from 90µg/kg/4 weeks to 180µg/kg/4 weeks.
The Committee on Drug I, Pharmaceutical Affairs and Food Sanitation Council (PAFSC) has taken the decision following the increased demand from concerned parties such as academics.